| | 
Part, Chapter, Paragraph
1 -, 1 | the European Commission D. G. Health and Consumers (
2 -, 1 | Antonella Calabrò, Marina D’Avanzo and Paola Marini
3 I, 2. 10. 3 | innovation for the uptake of R&D.~Launching of a public debate
4 I, 2. 10. 4(18)| De Scioli D. (2005). Differatiating
5 I, 2. 10. 4 | proprietary solutions and R&D resources can be created
6 I, 3. 4 | NIDI, Den Haag.~ ~Bloom D E, Trussell J (1984): What
7 II, 4. 3 | Montpellier, EHEMU.~ ~Kung, H., D. Hoyert, et al. (2007):
8 II, 4. 3 | 6): 590-597.~ ~Sullivan, D. F. (1971): A single index
9 II, 5. 2. 6 | Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor
10 II, 5. 2. 6 | MP, Feskens EJ, Kromhout D (1996). Blood pressure and
11 II, 5. 2. 6 | 1862.~Stamler J, Wentworth D, Neaton JD (1986). Is relationship
12 II, 5. 2. 6 | Donnell CJ, Kannel WB, Levy D (2001). Impact of high-normal
13 II, 5. 2. 7 | H, Sans S, and Kromhout D (2006): Dynamics of cardiovascular
14 II, 5. 2. 7 | Trojani M, Panico S, Vanuzzo D, Pilotto L, Cesana G, Ferrario
15 II, 5. 2. 7 | Donfrancesco C, Vanuzzo D, Chiodini P, Cesana G, Ferrario
16 II, 5. 2. 7 | S, Kesteloot H, Kromhout D on behalf of the Task Force (
17 II, 5. 2. 7 | M, Asplund K, rastenyte D, Kuulasma K, Vanuzzo D,
18 II, 5. 2. 7 | rastenyte D, Kuulasma K, Vanuzzo D, Tuomilehto J for the WHO
19 II, 5. 2. 7 | Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al for the WHO
20 II, 5. 2. 7 | Unal B, Critchley JA, Fidan D, Capewell S (2005): Life-Years
21 II, 5. 3. 9 | Santaquilani M, Roazzi P, Lisi D, EUROCARE Working Group (
22 II, 5. 4. 8 | 13(4), 245. 2001.~Boyle D, Cunningham S, Sullivan
23 II, 5. 5. 1 | Bille-Brahe U, De Leo D et al. (2004). Suicidal
24 II, 5. 5. 2 | Surr C, Boyle G and Brooker D (2005): Summary report for
25 II, 5. 5. 3 | 7. References~Alexander D, Rigby M, (in press, due
26 II, 5. 5. 3 | Adolescents, in press.~Alexander D, Rigby M, Frazzica R.G,
27 II, 5. 5. 3 | March 2008).~Berkman, N. D.; Lohr, K. N.; Bulik, C.
28 II, 5. 5. 3 | Leclercq C, Kafatos A, Molnar D, Marcos A, Castillo M, Dallongeville
29 II, 5. 5. 3 | 95.~Hoek H W, van Hoeken D, (2003): Review of the Prevalence
30 II, 5. 5. 3 | 63-71.~Fors BM, Isacson D, Bingefors K, Widerlöv B (
31 II, 5. 5. 3 | Neurosci 254(2):117-28.~Healy D, Harris M, Tranter R, Gutting
32 II, 5. 5. 3 | Terwilliger JD, Lichtermann D, Makikyro T, Suvisaari J,
33 II, 5. 5. 3 | Salokangas RK, Linszen D, Birchwood M, Juckel G,
34 II, 5. 5. 3 | 161-7.~Knapp M, McDaid D, Mossialos E, Thornicroft
35 II, 5. 5. 3 | PH, Tsai J, Yanos P, Roe D (2007): Associations of
36 II, 5. 5. 3 | 1991.~Mathers CD, Loncar D (2006): Projections of Global
37 II, 5. 5. 3 | 2511-2518.~Saha S, Chant D, McGrath J (2005): A systematic
38 II, 5. 5. 3 | 2(5):e141.~Saha S, Chant D, McGrrath J (2007): A systematic
39 II, 5. 5. 3 | Shorvon S, Perucca E, Fish D, Dodson E.) Oxford, Blackwell
40 II, 5. 5. 3 | Shorvon S, Perucca E, Fish D, Dodson E.) Oxford, Blackwell
41 II, 5. 5. 3 | 253.~Fraser RT, Clemmons D, Trejo W, Temkin NR (1983):
42 II, 5. 5. 3 | 362.~Taylor J, Chadwick D, Johnson T (1996): Risk
43 II, 5. 5. 3 | Vignatelli L, Tonon C, D’Alessandro R, on behalf
44 II, 5. 5. 3 | public awareness about MS; (d) the impact of different
45 II, 5. 5. 3 | level, among which vitamin D status with diet and sun
46 II, 5. 5. 3 | If sunlight or vitamin D are major environmental
47 II, 5. 5. 3 | remissions and plateaus; (d) primary-progressive MS (
48 II, 5. 5. 3 | Higginson I, Pitschnau-Michel D, Voltz D (2006) Position
49 II, 5. 5. 3 | Pitschnau-Michel D, Voltz D (2006) Position Paper Palliative
50 II, 5. 5. 3 | 2006;56(2):78-105~Horakova D (2004): Report of multiple
51 II, 5. 5. 3 | 36.~Milanov I, Georgiev D, Kmetska K, Jordanova L,
52 II, 5. 5. 3 | Neuroepidemiology 16:304-307~Miller D, Noseworthy J, Compston
53 II, 5. 5. 3 | B, Krtsch U, Burckhardt D, Nordman B (1989): Increasing
54 II, 5. 5. 3 | 79.~Pritchard C, Baldwin D, Mayers A (2004). Changing
55 II, 5. 5. 3 | 22.~Rothwell PM, Charlton D (1998): High incidence and
56 II, 5. 5. 3 | Trisolini M, Wiener J, Miller D (2002): Principles to promote
57 II, 5. 5. 3 | 2004; Chio et al, 1998; D’Alessandro et al, 1987;
58 II, 5. 5. 3 | studies (Schöffski and v.d. Schulenburg, 2007).~ ~PD,
59 II, 5. 5. 3 | 6.7. References~Aarsland D, Larsen JP, Tandberg E,
60 II, 5. 5. 3 | F, Amaducci L, Inzitari D (2000): Parkinson’s disease
61 II, 5. 5. 3 | Chio A, Magnani C, Schiffer D (1998): Prevalence of Parkinson’
62 II, 5. 5. 3 | Mov Disord 17(2):242-249.~D’Alessandro R, Gamberini
63 II, 5. 5. 3 | Naccarato S, Manzaroli D (1987): Prevalence of Parkinson’
64 II, 5. 5. 3 | Lees A, Rooney C, Burn D (2005): Population based
65 II, 5. 5. 3 | 250-255~Schöffski O, v.d. Schulenburg J-M., 2007.
66 II, 5. 5. 3 | Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm
67 II, 5. 5. 3 | Neurol 91:133-142.~Twelves D, Perkins KS, Counsell C (
68 II, 5. 6. 3 | inactivity, calcium or vitamin D deficiency or corticosteroid
69 II, 5. 6. 6 | Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt
70 II, 5. 6. 6 | Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke
71 II, 5. 6. 6 | JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (
72 II, 5. 6. 6 | 224-229~Croft P, Coggon D, Cruddas M, Cooper C (1992):
73 II, 5. 6. 6 | Ensrud KE, Cauley J, Black D, Vogt TM (1995): Risk factors
74 II, 5. 6. 6 | Osteoporos Int 15:38-42~Jonsson D and Husberg M (2000): Socioeconomic
75 II, 5. 6. 6 | Levy E, Ferme A, Perocheau D, Bono I (1993): [Socioeconomic
76 II, 5. 6. 6 | Lin CT, Albertson G, Price D, Swaney R, Anderson S, Anderson
77 II, 5. 6. 6 | B, Nessiøy I, Bruusgaard D, Rutle O (1995): Musculoskeletal
78 II, 5. 6. 6 | WE, Harrison B, Symmons D (2001) What is the natural
79 II, 5. 6. 6 | Finn JD, Lunt M, Purdie D, Reid DM, Rowe R, Woolf
80 II, 5. 6. 6 | Bendall H, Cooper C, Coggon D (2000) Back pain in Britain:
81 II, 5. 6. 6 | Sci Med 40:189-197~Symmons D, Harrison B (2000): Early
82 II, 5. 6. 6 | Oxford) 39:835-843~Symmons D, Mathers C, and Pfleger
83 II, 5. 6. 6 | Organization, Geneva~ ~Symmons D, Turner G, Webb R, Asten
84 II, 5. 6. 6 | Barrett E, Lunt M, Scott D, Silman A (2002): The prevalence
85 II, 5. 6. 6 | 793-800~Urwin M, Symmons D, Allison T, Brammah T, Busby
86 II, 5. 6. 6 | Chaussade S, Cucinotta D, Veale DJ, Martin-Mola E (
87 II, 5. 7. 1 | Otero et al., 2005; de Zeeuw D et al., 2005; Hallan et
88 II, 5. 7. 1 | dialysis or transplantation~5 D if dialysis (HD or PD)~ ~*
89 II, 5. 7. 7 | Baigent C, Burbury K, Wheeler D (2000): Premature cardiovascular
90 II, 5. 7. 7 | Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, Reynolds
91 II, 5. 7. 7 | 800-6.~Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers
92 II, 5. 7. 7 | Jan;16(1):180-8.~de Zeeuw D, Hillege HL, de Jong PE (
93 II, 5. 7. 7 | Chambless L, Merkin SS, Arnett D, Eigenbrodt M, Nieto FJ,
94 II, 5. 7. 7 | Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004):
95 II, 5. 7. 7 | Greene T, Rogers N, Roth D (1999): A more accurate
96 II, 5. 7. 7 | National Kidney Foundation. K/D The seventh report of the
97 II, 5. 8. 7 | Kreiss K, Mapp C, Milton D, Schwartz D, Toren K, Viegi
98 II, 5. 8. 7 | Mapp C, Milton D, Schwartz D, Toren K, Viegi G (2003):
99 II, 5. 8. 7 | Boutin-Forzano S, Moreau D, Kalaboka S, Gay E, Bonnefoy
100 II, 5. 8. 7 | Carrozzi L, Viegi G, Charpin D, Annesi-Maesano I. (2007) :
101 II, 5. 8. 7 | Housset B, Huchon G, Huas D, Godard P, Voinet C, Chanal
102 II, 5. 8. 7 | E, Nicolauu J, Eilstein D, Delmas M-C (2006): Deaths
103 II, 5. 8. 7 | 22: 485-489.~ ~Goodridge D., Lawson J., Duggleby W.,
104 II, 5. 8. 7 | Duggleby W.,Marciniuk D., Rennie D., Stang M (2008):.
105 II, 5. 8. 7 | W.,Marciniuk D., Rennie D., Stang M (2008):. Health
106 II, 5. 8. 7 | 16 April 2007)~ ~Gorecka D, Bednarek M, Nowinski A,
107 II, 5. 8. 7 | Halbert RJ, Isonaka S, George D, Iqbal A (2003): Interpreting
108 II, 5. 8. 7 | Garcia-Esteban R, Radon R, Jarvis D, Toren K, Künzli N, Norbäck
109 II, 5. 8. 7 | Toren K, Künzli N, Norbäck D, d'Errico A, Urrutia I,
110 II, 5. 8. 7 | K, Künzli N, Norbäck D, d'Errico A, Urrutia I, Payo
111 II, 5. 8. 7 | Zielinski J, Bednarek M, Gorecka D, Viegi G, Hurd SS, Fukuchi
112 II, 5. 9. 4 | allergen. Sensitization to D. Pteronyssinus, grass pollen
113 II, 5. 9. 4 | 54.8%. Sensitization to D. pteronyssinus, grass pollen
114 II, 5. 9. 7 | Austin JB, Burr M, Jeffs D (2004): Trends in prevalence
115 II, 5. 9. 7 | Hooper R, Kogevinas M, Jarvis D, Burney P. (2007a): Nu I.
116 II, 5. 9. 7 | Kogevinas M, Burney P, Jarvis D (2007b): Ge I. Allergy 62:
117 II, 5. 9. 7 | 2006~ ~Masoli M, Fabian D, Holt S, Beasley R, Global
118 II, 5. 9. 7 | Germany~ ~Holgate ST, Price D, Valovirta E (2006): Asthma
119 II, 5. 9. 7 | 2466-6-S1-S2).~ ~Jarvis D, Luczynska C, Chinn S, Potts
120 II, 5. 10. 5 | thereof (including lactose) (d)~- Nuts and products thereof (
121 II, 5. 10. 5 | from soybean sources.~ ~(d) whey used for making distillates
122 II, 5. 10. 7 | Gupta R, Sheikh A, Strachan D, Ross Anderson H (2003):
123 II, 5. 10. 7 | Keil T, Summers C, Gislason D, Zuidmeer L, Sodergren E,
124 II, 5. 11. 1 | heat and cold. Vitamin D is synthesized in the skin.
125 II, 5. 12. 5 | developed areas of the world (D'Argenio et al, 1989; Shapiro
126 II, 5. 12. 6 | is advisable. (Schuppan D, Afdhal NH, 2008)~ ~ ~
127 II, 5. 12. 7 | Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM,
128 II, 5. 12. 7 | Hepatology 27:914-919.~ ~D'Argenio P, Esposito D, Mele
129 II, 5. 12. 7 | D'Argenio P, Esposito D, Mele A, Ortolani G, Adamo
130 II, 5. 12. 7 | Negri E, Little D, Boiocchi M, La Vecchia
131 II, 5. 12. 7 | Messner M, Launois B, Samuel D, Cherqui D, et al (1999):
132 II, 5. 12. 7 | Launois B, Samuel D, Cherqui D, et al (1999): Evaluation
133 II, 5. 12. 7 | Endoscopy 34:690-697.~ ~Schuppan D, Afdhal NH (2008): Liver
134 II, 5. 14. 2 | recommended at age 12 and 15.~ ~d. Edentulous Prevalence~Proportion
135 II, 5. 14. 8 | Petersen PE, Bourgeois D, Bratthal D, Ogawa H (2005):
136 II, 5. 14. 8 | PE, Bourgeois D, Bratthal D, Ogawa H (2005): Oral health
137 II, 5. 14. 8 | Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day
138 II, 5. 15. 6 | 1060.~Kesselman I, Elstein D, Israeli A, Chertkoff R,
139 II, 6. 3. 7 | 2000 from Ghana or Côte d’Ivoire and Nigeria. No cases
140 II, 6. 3. 7 | 1999 (imported from Côte d’Ivoire), one from Belgium
141 II, 6. 4. 5 | controlled way in agriculture; d) reinforce and promote infection
142 II, 7. 7 | Organization.~ ~Körmer C, Smolka D (2008): Injuries to Vulnerable
143 II, 7. 7 | Office for Europe.~ ~Schopper D, Lormand JD, Waxweiler R (
144 II, 7. 7 | Organization.~ ~Shields N, Sethi D, Racioppi F, Yordi Aguirre
145 II, 7. 7 | Europe.~ ~Todd C, Skelton D. (2004): What are the main
146 II, 8. 2. 1 | Scheepers M, Kerr M, O’Hara D, Bainbridge D, Cooper S-A,
147 II, 8. 2. 1 | M, O’Hara D, Bainbridge D, Cooper S-A, Davis R, Fujiura
148 II, 8. 2. 2 | Eye 19:175-82~Pascolini D, Mariotti S, Pokharel GP,
149 II, 8. 2. 2 | Pararajasegaram R, Etya’ale D, Négrel A-D, et al. (2004):
150 II, 8. 2. 2 | Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram
151 II, 8. 2. 2 | S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram
152 II, 8. 2. 2 | 851~Resnikoff S, Pascolini D, Mariotti SP and Pokharel
153 II, 9 | Tables from 9.1.a to 9.1.d.~ ~Table 9.1a. Main risk
154 II, 9. 1. 1 | Sibony O, Oury JF, Luton D, Blot P (2002): Differences
155 II, 9. 1. 1 | 8.~Bertollini R, DiLallo D, Spadea T, Perucci C. Cesarean (
156 II, 9. 1. 1 | Meershoek AP, van Velzen D (1998): Contribution of
157 II, 9. 1. 1 | Manktelow B, Field DJ, James D (1999): Prediction of survival
158 II, 9. 1. 1 | SB, Moutquin JM, Farine D, Saigal S, Nimrod C, Kelly
159 II, 9. 1. 1 | Lorenz JM, Cleary-Goldman J, D'Alton ME, et al (2003):
160 II, 9. 1. 1 | Reempts P, Gortner L, Milligan D, Cuttini M, Petrou S, Agostino
161 II, 9. 1. 2 | termination of pregnancy d) the quality of treatment
162 II, 9. 1. 2 | of hospital episode data d) electronic access to birth
163 II, 9. 1. 2 | other health benefits.~ ~d) Public health measures
164 II, 9. 1. 2 | McDonnell R, Nelen V and Stone D (2005c): "Survey of Informed
165 II, 9. 1. 2 | Haeusler M, Jordan H, Tucker D, Stoll C, Feijoo M, Lillis
166 II, 9. 1. 2 | Stoll C, Feijoo M, Lillis D, Bianchi F (2005): "Trends
167 II, 9. 1. 2 | Wiesel A, Calzolari E, Stone D (2004): "Towards the Effective
168 II, 9. 1. 2 | Vigan C, Scarano G, Tucker D, Stoll C et al (2005): “
169 II, 9. 1. 2 | Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman E,
170 II, 9. 2. 7 | References~ ~Alexander D, Rigby M, Hillger C, Neumann
171 II, 9. 2. 7 | 809.~ ~Masoli M, Fabian D, Holt S, Beasley R (2004?):
172 II, 9. 2. 7 | 55-71.~ ~Neumark-Sztainer D; Wall M; Story M; Fulkerson
173 II, 9. 2. 7 | Ozanne SE, Fernandez-Twinn D, Hales CN (2005): Fetal
174 II, 9. 3. 1 | intake of calcium and vitamin D – and adequate physical activity
175 II, 9. 3. 1 | polishing. Calcium and vitamin D supplementation and pharmacologic
176 II, 9. 3. 1 | European Communities.~ ~Falzon D and Belghiti F (2007): Tuberculosis –
177 II, 9. 3. 1 | 15), pp 363-388~ ~Haslam, D (2007) The causes of male
178 II, 9. 3. 1 | Health Organization~ ~Wilkins D (2007): Report on the Expert
179 II, 9. 3. 2 | Sibony O, Oury JF, Luton D, Blot P (2002): Differences
180 II, 9. 3. 2 | Bertollini R, DiLallo D, Spadea T, Perucci C. Cesarean (
181 II, 9. 3. 2 | Meershoek AP, van Velzen D (1998): Contribution of
182 II, 9. 3. 2 | Manktelow B, Field DJ, James D (1999): Prediction of survival
183 II, 9. 3. 2 | SB, Moutquin JM, Farine D, Saigal S, Nimrod C, Kelly
184 II, 9. 3. 2 | Lorenz JM, Cleary-Goldman J, D'Alton ME, et al (2003):
185 II, 9. 3. 2 | mortality statistics. In: Hull D, editor. Recent Advances
186 II, 9. 3. 2 | Reempts P, Gortner L, Milligan D, Cuttini M, Petrou S, Agostino
187 II, 9. 3. 3 | information to be effective (Kirby D et al, 2006). Systematic
188 II, 9. 3. 3 | Observatoire Régional de Santé d’Ile de France.~Bochow M,
189 II, 9. 3. 3 | Saint-Louis à Bruxelles Centre d’études sociologiques (2006).
190 II, 9. 3. 3 | Health Metrics 2:5~Kirby D, Laris BA, Rolleri L (2006):
191 II, 9. 3. 3 | Singh S, Hodges Z, Patel D, Bajos N (2006): Sexual
192 II, 9. 4. 7 | S1: S110-S114~ ~Volkert D (2005): Abstract: Nutrition
193 II, 9. 5. 6 | accessed 12.07.07)~ ~Cutler D, Deaton A, Lleras-Muney
194 II, 9. 5. 6 | 279: 31 January~ ~Jernigan D H (2001): Global Status
195 II, 9. 5. 6 | Organization, Geneva~ ~Jernigan D H (2001): Global Status
196 II, 9. 5. 6 | accessed 07.07)~ ~Volkert D (2005): Nutrition and lifestyle
197 III, 10. 1. 3 | AK, Franklin BA, Buchner D, Daniles SR, Claytor RP (
198 III, 10. 1. 3 | Nutrition 24:885-895.~Meusel D, Höger C, Pérez-Rodrigo
199 III, 10. 1. 3 | Geneva, Switzerland.~Meusel D, Maywald U, Hach I, Kirch
200 III, 10. 1. 3 | 71-75.~Wagner N, Meusel D, Höger C, Kirch W (2005):
201 III, 10. 2. 1 | Marco R, Chinn S, Jarvis D, Svanes C, Heinrich J, Jõgi
202 III, 10. 2. 1 | Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day
203 III, 10. 2. 1 | Helakorpi et al., 2003)~ ~d) Lack of information on
204 III, 10. 2. 1 | June 2007).~ ~Glenister D (1996): Exercise and mental
205 III, 10. 2. 1 | Physiology, 99:765–770.~ ~Hunter D (2005): Proceedings of the
206 III, 10. 2. 1 | Turrini A, Saba A, Perrone D, Cialfa E, D'Amicis A (2001):
207 III, 10. 2. 1 | A, Perrone D, Cialfa E, D'Amicis A (2001): Food consumption
208 III, 10. 2. 1 | Scandinavian countries, 300µg/d of folate are recommended
209 III, 10. 2. 1 | vitamin B12 .~ ~Vitamin D and Calcium~ ~Vitamin D
210 III, 10. 2. 1 | D and Calcium~ ~Vitamin D differs from other vitamins
211 III, 10. 2. 1 | is intensified by vitamin D deficiency increasing the
212 III, 10. 2. 1 | ability to synthesize vitamin D also declines with age (
213 III, 10. 2. 1 | Food sources of vitamin D are rather scarce with fish
214 III, 10. 2. 1 | supply is often below 800 mg/d (Eurodiet 2000). The elderly
215 III, 10. 2. 1 | suffer from a lack of vitamin D as previously mentioned.
216 III, 10. 2. 1 | Intake (DRI)).~o Vitamin D. Because it is inexpensive
217 III, 10. 2. 1 | inexpensive to provide vitamin D and because many of the
218 III, 10. 2. 1 | calcium also used vitamin D supplementation, supplements
219 III, 10. 2. 1 | supplements of vitamin D are recommended for at-risk
220 III, 10. 2. 1 | international units) of vitamin D per day may be sufficient.~
221 III, 10. 2. 1 | adequate calcium, vitamin D and iron supply. Deficiencies
222 III, 10. 2. 1 | insufficient for vitamins B12 and D and for iron. Further emerging
223 III, 10. 2. 1 | 30:1265–1271.~ ~Jotangia D, Moody A, Stamatakis E,
224 III, 10. 2. 1 | Journal 309:57.~ ~Mansour D (2004): Implications of
225 III, 10. 2. 1 | examination surveys. Revue d’Epidémiologie et de Santé
226 III, 10. 2. 1 | Jēce I, Velika B, Grīnberga D, Villeruša A, Dzērve V,
227 III, 10. 2. 1 | Mozsáry E, Vitrai J, Hermann D, Boros J, Németh R, Kéki
228 III, 10. 2. 1 | 2001): Calcium and vitamin D nutrition and bone disease
229 III, 10. 2. 1 | Kroke A, Bamia C, Karalis D, Vineis P, Palli D, Bueno-de-Mesquita
230 III, 10. 2. 1 | Karalis D, Vineis P, Palli D, Bueno-de-Mesquita HB, Peeters
231 III, 10. 2. 1 | HB, Peeters PH, Engeset D, Hjartaker A, Navarro C,
232 III, 10. 2. 1 | MC, Peeters PH, Engeset D, Skeie G, Aller A, Amiano
233 III, 10. 2. 1 | van der Schouw YT, Engeset D, Skeie G, Tormo MJ, Ardanaz
234 III, 10. 2. 1 | Peeters PH, Skeie G, Engeset D, Charrondiere UR, Slimani
235 III, 10. 2. 1 | MC, Peeters PH, Engeset D, Skeie G, Slimani N, Riboli
236 III, 10. 2. 4 | 969-974.~ ~Childs B, Valle D (2000): Genetics, Biology
237 III, 10. 2. 4 | Dudas ME, Leung DHY, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo
238 III, 10. 2. 4 | 158:1245-1251.~ ~Ibarreta D, Bock, A.K., Klein C, Rodriguez-Cerezo
239 III, 10. 2. 4 | Cortina-Borja M, Warden DR, Smith D, Sleegens K, Prince JA,
240 III, 10. 2. 4 | Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai
241 III, 10. 2. 5 | Forsen T, Osmond C, Barker D, Eriksson J (2001): Association
242 III, 10. 3. 1 | the synthesis of vitamin D in the skin. Vitamin D is
243 III, 10. 3. 1 | vitamin D in the skin. Vitamin D is essential for the metabolism
244 III, 10. 3. 1 | in the body and vitamin D deficiency leads to de-calcification
245 III, 10. 3. 1 | 38, 99-166.~Darby S, Hill D, Auvinen A, Barros-Dios
246 III, 10. 3. 1 | Leuraud K, Billon S, Bergot D, Tirmarche M, Caër S, Quesne
247 III, 10. 3. 1 | Caër S, Quesne B, Laurier D (2007): Lung cancer risk
248 III, 10. 3. 1 | Berglund B, Lindvall T, Schwela D.~World Health Organization
249 III, 10. 4. 2 | the food production chain; d) food safety: limits on
250 III, 10. 4. 2 | experienced staff are present; (d) that they have appropriate
251 III, 10. 5. 1 | 2001, 285:535–539.~Norback D, Tao J, Mi YL, Ferm M, (
252 III, 10. 5. 1 | Wang Z, Zhang Z, Norbäck D, (2008): Asthmatic symptoms
253 III, 10. 5. 2 | O'Reilly G, O'Reilly D, Rosato M, Connolly S (2007):
254 III, 10. 5. 3 | University Press.~ ~Walters D (2007): An International
255 III, 10. 6. 1 | Roberts C, Smith R, Currie D, Picket W, Richter M, Morgan
256 IV, 11. 1. 3 | purchasing from provision; and d) reforming payment mechanisms.~ ~
257 IV, 11. 6. 4 | Cotisations de Sécurité et d’Allocations Familiales at
258 IV, 11. 6. 5 | Communities.~ ~Balabanova D, McKee M (2002): "Understanding
259 IV, 11. 6. 5 | 3): 10-20.~ ~Blumenthal D (1996): "Part 1: Quality
260 IV, 11. 6. 5 | 9.~ ~Claridge T, Parker D et al. (2006): Pathways
261 IV, 11. 6. 5 | XL: 881-906.~ ~De Graeve D, Van Ourti T (2003): The
262 IV, 11. 6. 5 | eurobarometers_en.htm.~ ~Evans D, Edejer T et al. (2001): "
263 IV, 11. 6. 5 | OECD.~ ~Kelly MP, McDaid D et al. (2005): Economic
264 IV, 11. 6. 5 | Paper No. 13.~ ~McCarthy D, Blumenthal D (2006): Committed
265 IV, 11. 6. 5 | McCarthy D, Blumenthal D (2006): Committed to Safety:
266 IV, 11. 6. 5 | Commonwealth Fund.~ ~McDaid D, Knapp M et al. (2005):
267 IV, 11. 6. 5 | Systems and Policies.~ ~McDaid D, Thornicroft G (2005): Mental
268 IV, 11. 6. 5 | 205.~ ~Mossialos E, Brogan D et al. (2006): "Pharmaceutical
269 IV, 11. 6. 5 | 361: 1817-20.~ ~Navarro D (2000): "Assessment of the
270 IV, 11. 6. 5 | 108.~ ~Retzlaff-Roberts D, Chang CF et al. (2004): "
271 IV, 11. 6. 5 | 76.~ ~Rizzo J, Blumenthal D (1996): "Is the target income
272 IV, 11. 6. 5 | and Policies.~ ~Sappington D (1991): "Incentives in Principal-Agent
273 IV, 12. 10 | 2006 Campaign: FA C T S A N D A D V I C E~about smoking
274 IV, 12. 10 | Campaign: FA C T S A N D A D V I C E~about smoking and
275 IV, 12. 10 | vegetables, preferably 600 g/d for adults and children (>
276 IV, 12. 10 | years of age) and 400 g/d for children (4-10 years
277 IV, 13. 7. 2 | private investment in R&D; location advantages for
278 IV, 13. 7. 2 | location advantages for R&D and production facilities;
|
|
| |
